| Literature DB >> 33068051 |
Petar M Seferović1,2, Gabriele Fragasso3, Mark Petrie4, Wilfried Mullens5,6, Roberto Ferrari7, Thomas Thum8, Johann Bauersachs9, Stefan D Anker10,11, Robin Ray12, Yuksel Çavuşoğlu13, Marija Polovina1,14, Marco Metra15, Giuseppe Ambrosio16, Krishna Prasad17, Jelena Seferović1,18, Pardeep S Jhund19, Giuseppe Dattilo20, Jelena Čelutkiene21, Massimo Piepoli22, Brenda Moura23, Ovidiu Chioncel24,25, Tuvia Ben Gal26, Stephane Heymans27, Tiny Jaarsma28, Loreena Hill29, Yuri Lopatin30, Alexander R Lyon31, Piotr Ponikowski32, Mitja Lainščak33,34, Ewa Jankowska32, Christian Mueller35, Francesco Cosentino36, Lars H Lund37, Gerasimos S Filippatos38, Frank Ruschitzka39, Andrew J S Coats40, Giuseppe M C Rosano41.
Abstract
The Heart Failure Association (HFA) of the European Society of Cardiology (ESC) has recently issued a position paper on the role of sodium-glucose co-transporter 2 (SGLT2) inhibitors in heart failure (HF). The present document provides an update of the position paper, based of new clinical trial evidence. Accordingly, the following recommendations are given: • Canagliflozin, dapagliflozin empagliflozin, or ertugliflozin are recommended for the prevention of HF hospitalization in patients with type 2 diabetes mellitus and established cardiovascular disease or at high cardiovascular risk. • Dapagliflozin or empagliflozin are recommended to reduce the combined risk of HF hospitalization and cardiovascular death in symptomatic patients with HF and reduced ejection fraction already receiving guideline-directed medical therapy regardless of the presence of type 2 diabetes mellitus.Entities:
Keywords: Cardiovascular outcomes; Heart failure; Renal function; Sodium-glucose co-transporter 2 inhibitors; Type 2 diabetes mellitus
Mesh：
Substances：
Year: 2020 PMID： 33068051 DOI： 10.1002/ejhf.2026
Source DB: PubMed Journal: Eur J Heart Fail ISSN： 1388-9842 Impact factor: 15.534